Scholar Rock Stock Price, News & Analysis (NASDAQ:SRRK) $18.25 +0.70 (+3.99%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$17.88▼$19.5350-Day Range$6.52▼$18.2552-Week Range$5.56▼$19.53Volume1.68 million shsAverage Volume725,535 shsMarket Capitalization$1.32 billionP/E RatioN/ADividend YieldN/APrice Target$24.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Scholar Rock MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside35.6% Upside$24.75 Price TargetShort InterestBearish14.28% of Shares Sold ShortDividend StrengthN/ASustainability-0.62Upright™ Environmental ScoreNews Sentiment0.34Based on 2 Articles This WeekInsider TradingAcquiring Shares$30.09 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.96) to ($1.87) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.42 out of 5 starsMedical Sector297th out of 933 stocksBiological Products, Except Diagnostic Industry50th out of 160 stocks 3.5 Analyst's Opinion Consensus RatingScholar Rock has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.75, Scholar Rock has a forecasted upside of 35.6% from its current price of $18.25.Amount of Analyst CoverageScholar Rock has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.28% of the outstanding shares of Scholar Rock have been sold short.Short Interest Ratio / Days to CoverScholar Rock has a short interest ratio ("days to cover") of 15.4, which indicates bearish sentiment.Change versus previous monthShort interest in Scholar Rock has recently decreased by 0.10%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldScholar Rock does not currently pay a dividend.Dividend GrowthScholar Rock does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreScholar Rock has received a 73.13% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Preclinical research services for physical health", "Clinical research services for cancer", and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Scholar Rock is -0.62. Previous Next 1.9 News and Social Media Coverage News SentimentScholar Rock has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Scholar Rock this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for SRRK on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Scholar Rock to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Scholar Rock insiders have bought 6,583.01% more of their company's stock than they have sold. Specifically, they have bought $30,091,527.00 in company stock and sold $450,269.00 in company stock.Percentage Held by Insiders26.20% of the stock of Scholar Rock is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.08% of the stock of Scholar Rock is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Scholar Rock are expected to grow in the coming year, from ($1.96) to ($1.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Scholar Rock is -9.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Scholar Rock is -9.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioScholar Rock has a P/B Ratio of 3.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Scholar Rock Stock (NASDAQ:SRRK)Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, fibrosis, and iron-restricted anemia. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.Read More SRRK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SRRK Stock News HeadlinesDecember 10, 2023 | finance.yahoo.comInsider Sell: COO & CFO Edward Myles Sells 24,914 Shares of Scholar Rock Holding Corp (SRRK)December 10, 2023 | benzinga.comScholar Rock Holding Stock (NASDAQ:SRRK) Dividends: History, Yield and DatesDecember 10, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.December 10, 2023 | americanbankingnews.comScholar Rock (NASDAQ:SRRK) Shares Gap Up to $17.55December 3, 2023 | americanbankingnews.comScholar Rock (NASDAQ:SRRK) Sets New 1-Year High at $13.64November 12, 2023 | finance.yahoo.comScholar Rock Holding Corporation (NASDAQ:SRRK) Q3 2023 Earnings Call TranscriptNovember 9, 2023 | markets.businessinsider.comPromising Future for Scholar Rock Holding Corporation: Buy Rating Justified by Potential Drug Approvals and Obesity Market ProspectsNovember 9, 2023 | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Scholar Rock Holding (SRRK)December 10, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 7, 2023 | finance.yahoo.comScholar Rock Holding Corp (SRRK) Reports Q3 2023 Financial ResultsNovember 7, 2023 | seekingalpha.comScholar Rock Holding Corporation 2023 Q3 - Results - Earnings Call PresentationNovember 7, 2023 | finance.yahoo.comScholar Rock Reports Third Quarter 2023 Financial Results and Highlights Business ProgressNovember 6, 2023 | finance.yahoo.comWall Street Analysts See a 99.11% Upside in Scholar Rock Holding Corporation (SRRK): Can the Stock Really Move This High?November 4, 2023 | finance.yahoo.comInsider Sell: Edward Myles Sells 35,007 Shares of Scholar Rock Holding Corp (SRRK)November 3, 2023 | businesswire.comScholar Rock Presents New Data from Phase 1 DRAGON Trial Showing Promising Anti-Tumor Activity in Anti-PD-1 Resistant Metastatic ccRCC Patients and Supporting SRK-181 Continued ...November 3, 2023 | finance.yahoo.comScholar Rock Presents New Data from Phase 1 DRAGON Trial Showing Promising Anti-Tumor Activity in Anti-PD-1 Resistant Metastatic ccRCC Patients and Supporting SRK-181 Continued TolerabilityNovember 2, 2023 | msn.comScholar Rock Holding (SRRK) Price Target Increased by 9.09% to 24.48October 31, 2023 | finance.yahoo.comHere's Why 'Trend' Investors Would Love Betting on Scholar Rock Holding Corporation (SRRK)October 26, 2023 | msn.comJefferies Upgrades Scholar Rock Holding (SRRK)October 25, 2023 | seekingalpha.comScholar Rock: SMA Data Readout In 2024 Makes This Worth A LookOctober 24, 2023 | msn.comJefferies upgrades Scholar Rock to buy; cites SMA, obesity drug assetsOctober 24, 2023 | finance.yahoo.comAll You Need to Know About Scholar Rock Holding Corporation (SRRK) Rating Upgrade to Strong BuyOctober 23, 2023 | businesswire.comScholar Rock to Host Conference Call to Discuss Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023October 19, 2023 | businesswire.comScholar Rock to Present Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 38 th Annual MeetingOctober 19, 2023 | benzinga.comScholar Rock Holding Insider Trades Send a SignalOctober 19, 2023 | finance.yahoo.comWall Street Analysts Think Scholar Rock Holding Corporation (SRRK) Could Surge 203.99%: Read This Before Placing a BetOctober 19, 2023 | finance.yahoo.comScholar Rock to Present Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 38th Annual MeetingSee More Headlines Receive SRRK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Scholar Rock and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today12/10/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/05/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SRRK CUSIPN/A CIK1727196 Webwww.scholarrock.com Phone(857) 259-3860Fax866-493-4935Employees114Year FoundedN/APrice Target and Rating Average Stock Price Target$24.75 High Stock Price Target$30.00 Low Stock Price Target$20.00 Potential Upside/Downside+35.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-134,500,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-74.00% Return on Assets-52.60% Debt Debt-to-Equity Ratio0.30 Current Ratio8.55 Quick Ratio8.55 Sales & Book Value Annual Sales$33.19 million Price / Sales39.67 Cash FlowN/A Price / Cash FlowN/A Book Value$5.04 per share Price / Book3.62Miscellaneous Outstanding Shares72,140,000Free Float53,242,000Market Cap$1.32 billion OptionableNot Optionable Beta0.66 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Jay T. Backstrom M.D. (Age 68)M.P.H., President, CEO & Director Comp: $686.49kMr. Edward H. Myles MBA (Age 51)CFO, COO & Treasurer Comp: $668.49kMs. Junlin Ho J.D. (Age 44)General Counsel & Corporate Secretary Comp: $563.73kMs. Catherine HuVice President of Investor Relations & Corporate CommunicationsMs. Caryn Parlavecchio (Age 51)Chief Human Resources Officer Ms. Lisa Amaya PriceSenior Vice President of Human ResourcesMs. Erin Moore (Age 48)Senior Vice President of Finance Mr. Ryan IarrobinoSenior Vice President of Clinical Development & OperationsDr. Jing L. Marantz M.B.A. (Age 58)M.D., Ph.D., Chief Medical Officer Ms. Tracey M. Sacco M.B.A. (Age 47)Chief Commercial Officer More ExecutivesKey CompetitorsKymera TherapeuticsNASDAQ:KYMRInhibrxNASDAQ:INBXApogee TherapeuticsNASDAQ:APGEVir BiotechnologyNASDAQ:VIRBioCryst PharmaceuticalsNASDAQ:BCRXView All CompetitorsInsiders & InstitutionsAmerican Century Companies Inc.Bought 6,538 shares on 11/30/2023Ownership: 0.038%Deutsche Bank AGBought 7,655 shares on 11/24/2023Ownership: 0.030%Polar Capital Holdings PlcBought 1,501,926 shares on 11/22/2023Ownership: 2.082%The Manufacturers Life Insurance Company Bought 4,797 shares on 11/15/2023Ownership: 0.265%Alps Advisors Inc.Bought 1,628 shares on 11/15/2023Ownership: 0.074%View All Insider TransactionsView All Institutional Transactions SRRK Stock Analysis - Frequently Asked Questions Should I buy or sell Scholar Rock stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SRRK shares. View SRRK analyst ratings or view top-rated stocks. What is Scholar Rock's stock price target for 2024? 4 analysts have issued 1-year price objectives for Scholar Rock's shares. Their SRRK share price targets range from $20.00 to $30.00. On average, they anticipate the company's stock price to reach $24.75 in the next year. This suggests a possible upside of 35.6% from the stock's current price. View analysts price targets for SRRK or view top-rated stocks among Wall Street analysts. How have SRRK shares performed in 2023? Scholar Rock's stock was trading at $9.05 at the beginning of 2023. Since then, SRRK stock has increased by 101.7% and is now trading at $18.25. View the best growth stocks for 2023 here. When is Scholar Rock's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024. View our SRRK earnings forecast. How were Scholar Rock's earnings last quarter? Scholar Rock Holding Co. (NASDAQ:SRRK) released its quarterly earnings results on Tuesday, November, 7th. The company reported ($0.53) earnings per share for the quarter, meeting the consensus estimate of ($0.53). During the same quarter last year, the business earned ($0.55) earnings per share. What other stocks do shareholders of Scholar Rock own? Based on aggregate information from My MarketBeat watchlists, some companies that other Scholar Rock investors own include Fulcrum Therapeutics (FULC), Coherus BioSciences (CHRS), CTI BioPharma (CTIC), Exelixis (EXEL), GlycoMimetics (GLYC), Nektar Therapeutics (NKTR), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV) and Atara Biotherapeutics (ATRA). When did Scholar Rock IPO? (SRRK) raised $76 million in an initial public offering (IPO) on Thursday, May 24th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Scholar Rock's major shareholders? Scholar Rock's stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (14.24%), Redmile Group LLC (8.42%), Polar Capital Holdings Plc (2.08%), Laurion Capital Management LP (0.98%), Northern Trust Corp (0.73%) and TD Asset Management Inc (0.60%). Insiders that own company stock include Amir Nashat, Caryn Parlavecchio, Edward H Myles, Gregory John Carven, Jeffrey S Flier, Michael Gilman, Mo Qatanani, Public Equities LP Invus and Samsara Biocapital Gp, Llc. View institutional ownership trends. How do I buy shares of Scholar Rock? Shares of SRRK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:SRRK) was last updated on 12/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scholar Rock Holding Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.